These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 30386878)

  • 1. Cell-based assays and molecular dynamics analysis of a boron-containing agonist with different profiles of binding to human and guinea pig beta2 adrenoceptors.
    Soriano-Ursúa MA; Bello M; Hernández-Martínez CF; Santillán-Torres I; Guerrero-Ramírez R; Correa-Basurto J; Arias-Montaño JA; Trujillo-Ferrara JG
    Eur Biophys J; 2019 Jan; 48(1):83-97. PubMed ID: 30386878
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Insights on the role of boron containing moieties in the design of new potent and efficient agonists targeting the β2 adrenoceptor.
    Soriano-Ursúa MA; Arias-Montaño JA; Correa-Basurto J; Hernández-Martínez CF; López-Cabrera Y; Castillo-Hernández MC; Padilla-Martínez II; Trujillo-Ferrara JG
    Bioorg Med Chem Lett; 2015 Feb; 25(4):820-5. PubMed ID: 25592716
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cell-based and in-silico studies on the high intrinsic activity of two boron-containing salbutamol derivatives at the human β₂-adrenoceptor.
    Soriano-Ursúa MA; McNaught-Flores DA; Nieto-Alamilla G; Segura-Cabrera A; Correa-Basurto J; Arias-Montaño JA; Trujillo-Ferrara JG
    Bioorg Med Chem; 2012 Jan; 20(2):933-41. PubMed ID: 22182578
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design, synthesis and in vitro evaluation of (R)-4-(2-(tert-butylamino)-1-hydroxyethyl)-2-(hydroxymethyl)phenyl hydrogen phenylboronate: a novel salbutamol derivative with high intrinsic efficacy on the β2 adrenoceptor.
    Soriano-Ursúa MA; Correa-Basurto J; Valencia-Hernández I; Amezcua-Gutiérrez MA; Padilla-Martínez II; Trujillo-Ferrara JG
    Bioorg Med Chem Lett; 2010 Oct; 20(19):5623-9. PubMed ID: 20805027
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Understanding the effects on constitutive activation and drug binding of a D130N mutation in the β2 adrenergic receptor via molecular dynamics simulation.
    Zhu Y; Yuan Y; Xiao X; Zhang L; Guo Y; Pu X
    J Mol Model; 2014 Nov; 20(11):2491. PubMed ID: 25342155
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synthesis, pharmacological and in silico evaluation of 1-(4-di-hydroxy-3,5-dioxa-4-borabicyclo[4.4.0]deca-7,9,11-trien-9-yl)-2-(tert-butylamino)ethanol, a compound designed to act as a beta2 adrenoceptor agonist.
    Soriano-Ursúa MA; Valencia-Hernández I; Arellano-Mendoza MG; Correa-Basurto J; Trujillo-Ferrara JG
    Eur J Med Chem; 2009 Jul; 44(7):2840-6. PubMed ID: 19168263
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structure-Based Prediction of G-Protein-Coupled Receptor Ligand Function: A β-Adrenoceptor Case Study.
    Kooistra AJ; Leurs R; de Esch IJ; de Graaf C
    J Chem Inf Model; 2015 May; 55(5):1045-61. PubMed ID: 25848966
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Influence of lipid composition on the structural stability of g-protein coupled receptor.
    Mahmood I; Liu X; Neya S; Hoshino T
    Chem Pharm Bull (Tokyo); 2013; 61(4):426-37. PubMed ID: 23546002
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long Receptor Residence Time of C26 Contributes to Super Agonist Activity at the Human β2 Adrenoceptor.
    Rosethorne EM; Bradley ME; Gherbi K; Sykes DA; Sattikar A; Wright JD; Renard E; Trifilieff A; Fairhurst RA; Charlton SJ
    Mol Pharmacol; 2016 Apr; 89(4):467-75. PubMed ID: 26772612
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Studies on the interactions between β2 adrenergic receptor and Gs protein by molecular dynamics simulations.
    Feng Z; Hou T; Li Y
    J Chem Inf Model; 2012 Apr; 52(4):1005-14. PubMed ID: 22404225
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The reassertion profiles of long acting β2-adrenoceptor agonists in the guinea pig isolated trachea and human recombinant β2-adrenoceptor.
    Patel S; Summerhill S; Stanley M; Perros-Huguet C; Trevethick MA
    Pulm Pharmacol Ther; 2011 Apr; 24(2):247-55. PubMed ID: 21134482
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Stereoselective binding of agonists to the β
    Plazinska A; Plazinski W
    Mol Biosyst; 2017 May; 13(5):910-920. PubMed ID: 28338133
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative Docking to Distinct G Protein-Coupled Receptor Conformations Exclusively Yields Ligands with Agonist Efficacy.
    Scharf MM; Bünemann M; Baker JG; Kolb P
    Mol Pharmacol; 2019 Dec; 96(6):851-861. PubMed ID: 31624135
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In silico analysis of the binding of agonists and blockers to the β2-adrenergic receptor.
    Vilar S; Karpiak J; Berk B; Costanzi S
    J Mol Graph Model; 2011 Apr; 29(6):809-17. PubMed ID: 21334234
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differences between G-Protein-Stabilized Agonist-GPCR Complexes and their Nanobody-Stabilized Equivalents.
    Saleh N; Ibrahim P; Clark T
    Angew Chem Int Ed Engl; 2017 Jul; 56(31):9008-9012. PubMed ID: 28481446
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Principles of Ligand Specificity on beta-2-adrenergic receptor.
    Chan HC; Filipek S; Yuan S
    Sci Rep; 2016 Oct; 6():34736. PubMed ID: 27703221
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design, synthesis and biological evaluation of 5-(2-amino-1-hydroxyethyl)-8-hydroxyquinolin-2(1H)-one derivatives as potent β
    Xing G; Pan L; Yi C; Li X; Ge X; Zhao Y; Liu Y; Li J; Woo A; Lin B; Zhang Y; Cheng M
    Bioorg Med Chem; 2019 Jun; 27(12):2306-2314. PubMed ID: 30392952
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Energy Landscapes Reveal Agonist Control of G Protein-Coupled Receptor Activation via Microswitches.
    Fleetwood O; Matricon P; Carlsson J; Delemotte L
    Biochemistry; 2020 Feb; 59(7):880-891. PubMed ID: 31999436
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A cell-based assay to assess the persistence of action of agonists acting at recombinant human beta(2) adrenoceptors.
    Summerhill S; Stroud T; Nagendra R; Perros-Huguet C; Trevethick M
    J Pharmacol Toxicol Methods; 2008; 58(3):189-97. PubMed ID: 18652905
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro pharmacological characterization of vilanterol, a novel long-acting β2-adrenoceptor agonist with 24-hour duration of action.
    Slack RJ; Barrett VJ; Morrison VS; Sturton RG; Emmons AJ; Ford AJ; Knowles RG
    J Pharmacol Exp Ther; 2013 Jan; 344(1):218-30. PubMed ID: 23131596
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.